BC Week In Review | Jan 13, 2014
Clinical News

ARRY-614: Phase I data

The open-label, dose-escalation, U.S. Phase I ARRY-614-112 trial in 71 evaluable patients with low- to intermediate-1-risk MDS showed that oral ARRY-614 led to hematologic improvement according to 2006 International Working Group (IWG) criteria in 14...
BioCentury | Oct 7, 2013

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Aug 12, 2013
Company News

Array BioPharma hematology, cancer news

Array said it cut headcount by 20% to about 200 to focus development and commercialization resources on hematology and cancer programs. Array said the headcount reductions came mainly from its drug discovery organization, which the...
BC Week In Review | Jan 9, 2012
Clinical News

ARRY-614: Phase I data

An open-label, dose-escalation Phase I trial in 44 evaluable patients with low to intermediate-1 risk MDS showed that total daily doses of 400, 600, 900 and 1,200 mg ARRY-614 led to hematologic improvement response rates...
BioCentury | Aug 22, 2011

Checkpoint match

With a pair of checkpoint kinase 1 inhibitors at similar stages of development, Genentech Inc. and Array BioPharma Inc. saw an opportunity for both companies to benefit by combining programs while ensuring neither has an...
BioCentury | Jul 4, 2011

2Q Stock Wrap-Up: Stand and deliver

Several market cap bands tracked by BioCentury did well last quarter, as investors rewarded late-stage data and transformative deals. The NYSE Arca Biotechnology Index and the BioCentury 100 each gained 7% in 2Q, while the...
BC Week In Review | Jun 20, 2011
Company News

Array BioPharma cancer news

The restructuring is expected to save about $20 million in its fiscal year ending June 30, 2012. At March 31, Array had $75.8 million in cash and a nine-month operating loss of $24.6 million. Array...
BC Extra | Jun 15, 2011
Top Story

Array restructuring

Array BioPharma Inc. (NASDAQ:ARRY) will restructure and reduce headcount by 70 (22%) to 255 to save cash. The cuts will primarily affect discovery research and support positions. Array said it is now seeking to partner...
BioCentury | Apr 26, 2010

Ready to graduate

Array BioPharma Inc. believes its latest deal could be the last time it out-licenses worldwide rights to assets created by its small molecule discovery and design platform. Last week's deal with Novartis AG , plus a...
BC Week In Review | Nov 16, 2009
Clinical News

ARRY-614: Phase I started

Array began an open-label, U.S. Phase I trial to evaluate oral ARRY-614 in about 50 patients. Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo.   Product: ARRY-614   Business: Cancer   Molecular target: p38 mitogen-activated protein kinase...
Items per page:
1 - 10 of 16